IP Library Patent Application 17861226
Patent Application
App. No. 17/861,226

METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/861,226
Abstract

This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.

Claims (21)

1 - 7 . (canceled)

8 . A sotalol hydrochloride dosing method, the method comprising:

(1) administering a single IV dosage of sotalol hydrochloride, for a period of 1 hour, to a subject who is under QTc monitoring, wherein the single IV dosage is administered to the subject in an amount of about 55-128 mg;

(2) monitoring QTc during the administering of the IV; and

(3) for the subject who's QTc during the administering of the IV is less than a 20% increase from baseline, administering an oral dose after completion of the single IV dosage.

9 . The method of claim 8 , further comprising repeating oral administration of sotalol hydrochloride at least once at a selected interval.

10 . The method of claim 9 , wherein the administering of the oral dose and the repeating are performed according to a once daily or twice daily schedule.

11 . The method of claim 9 , wherein the interval is selected from 12 hours, 24 hours, or 48 hours.

12 . The method of claim 9 , wherein the administering of the oral dose is performed 2-12 hours after completion of the single IV dosage of sotalol hydrochloride.

13 . The method of claim 12 , wherein the administering of the oral dose is performed 2-4 hours after completion of the single IV dosage of sotalol hydrochloride.

14 . The method of claim 13 , wherein the repeating of the oral administration is performed at least once at a 12- to 48-hour interval.

15 . The method of claim 12 , wherein the administering of the oral dose is performed 4-12 hours after completion of the single IV dosage of sotalol hydrochloride.

16 . The method of claim 15 , wherein the repeating of the oral administration is performed at least once at a 12- to 48-hour interval.

17 . The method of claim 9 , further comprising assessing a QTc of the subject after each of the IV dosage, a first oral dosage, and a second oral dosage.

18 . The method of claim 17 , wherein the assessing of the QTc after each of the IV dosage, the first oral dosage, and the second oral dosage is completed in less than 24 hours.

19 . The method of claim 18 , wherein each QTc is less than a 20% increase from a baseline QTc of the subject.

20 . The method of claim 8 , wherein the sotalol hydrochloride is administered to treat or prevent atrial fibrillation or atrial flutter in the subject.

21 . The method of claim 8 , wherein the single IV dosage is administered to the subject in an amount of about 88-105.6 mg.

22 . The method of claim 21 , wherein the subject had received oral sotalol hydrochloride prior to the administering of the IV dosage.

23 . The method of claim 8 , wherein the subject had received oral sotalol hydrochloride prior to the administering of the IV dosage.

24 . The method of claim 8 , wherein the subject had not previously received sotalol hydrochloride.

Assignments (2)
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Jul 14, 2023
From: SAGARD HEALTHCARE ROYALTY PARTNERS, LP
To: SAGARD HEALTHCARE PARTNERS (DELAWARE) LP
Reel/Frame 064275/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2022
From: SOMBERG, JOHN CHARIN; KASHFIAN, BRANDON IRA; MOLNAR, JANOS
To: ALTATHERA PHARMACEUTICALS LLC
Reel/Frame 061997/0302 →